Skip to content
value.today

Immusoft Corp

Total raised
$40 M
5 rounds on record
Latest round
$5 M
May 2024
First round on record
Aug 2014
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Immusoft Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$5 MNo. 5$2 to $10 million

Immusoft Corp: Raise no. 5, May 2024

Investors in this round

25 investors had bought by the notice of Jun 12, 2024: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean Ainsworth · Executive Officer, Director
  • Anthony Sun · Director
  • Cam Gallahger · Director
  • Julia Moore · Director
  • Matthew Scholz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Ainsworth, Ceo. Source: SEC Form D, newest notice filed Jun 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Sep 2020$10 MNo. 4$10 to $50 million

Immusoft Corp: Raise no. 4, Sep 2020

Investors in this round

32 investors had bought by the notice of Mar 2, 2021: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $11 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sean c/o Ainsworth · Executive Officer, Director
  • Anthony c/o Sun · Director
  • Julia c/o Moore · Director
  • Matthew c/o Scholz · Director
  • Wendell c/o King · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Ainsworth, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Mar 2, 2021. Read the notice at the SEC.

equity, optionsSEC
Jan 2018$20 MNo. 3$10 to $50 million

Immusoft Corp: Raise no. 3, Jan 2018

Investors in this round

64 investors had bought by the notice of Jan 25, 2019: 64 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $23 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rich Vincent · Executive Officer
  • Sean Ainsworth · Executive Officer, Director
  • Anthony Sun · Director
  • Julia Moore · Director
  • Matthew Scholz · Director
  • Wendell King · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Ainsworth, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 25, 2019. Read the notice at the SEC.

equity, optionsSEC
Oct 2016$3 MNo. 2$2 to $10 million

Immusoft Corp: Raise no. 2, Oct 2016

Investors in this round

11 investors had bought by the notice of Nov 1, 2016: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Scholz · Executive Officer, Director
  • Mark Ahn, Ph.D. · Director
  • Wendell King · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Scholz, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 1, 2016. Read the notice at the SEC.

equitySEC
Aug 2014$2 MNo. 1$2 to $10 million

Immusoft Corp: Raise no. 1, Aug 2014

Investors in this round

11 investors had bought by the notice of Aug 20, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Eric Garcia · Executive Officer
  • Matthew Scholz · Executive Officer, Director
  • Mark Ahn, Ph.D. · Director
  • Richard Chin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Scholz, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 20, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immusoft Corp chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2024

That is all the official record says: Immusoft Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Immusoft Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 64 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immusoft Corp
NameRoleNamed in
Sean AinsworthExecutive officerJun 2024
Sean c/o AinsworthExecutive officerMar 2021
Rich VincentExecutive officerJan 2019
Eric HerbigExecutive officerJan 2018
Matthew ScholzExecutive officerJan 2018
Scott McIvorExecutive officerJan 2018
Eric GarciaExecutive officerAug 2014
Anthony SunDirectorJun 2024
Cam GallahgerDirectorJun 2024
Julia MooreDirectorJun 2024
Matthew ScholzDirectorJun 2024
Sean AinsworthDirectorJun 2024
Anthony c/o SunDirectorMar 2021
Julia c/o MooreDirectorMar 2021
Matthew c/o ScholzDirectorMar 2021
Sean c/o AinsworthDirectorMar 2021
Wendell c/o KingDirectorMar 2021
Wendell KingDirectorJan 2019
Mark Ahn, Ph.D.DirectorJan 2018
Richard Chin, M.D.DirectorAug 2014